NCT01929629 is a Phase 1 clinical trial of Part A in Gonococcal (GC) Infection, sponsored by AstraZeneca.

Who is sponsoring NCT01929629?

NCT01929629 is sponsored by AstraZeneca.

What drugs are being tested in NCT01929629?

Interventions in NCT01929629: Part A, Part B.

What condition does NCT01929629 study?

NCT01929629 studies Gonococcal (GC) Infection.

Is NCT01929629 still recruiting?

NCT01929629 is currently completed. Last updated 14 April 2014.

Last reviewed 2014-04-14 · How we verify

NCT01929629

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to Assess the Effect of Food in Healthy Adult Volunteers

Completed Phase 1 Last updated 14 April 2014

What this trial tests

Phase 1 trial testing Part A in Gonococcal (GC) Infection in 100 participants. Completed in 1 March 2014.

Timeline

1 September 2013

Primary endpoint
1 March 2014

1 March 2014

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	100
Start date	1 September 2013
Primary completion	1 March 2014
Estimated completion	1 March 2014
Sites	1 location across United States

Drugs / interventions tested

Part A — full drug profile →
Part B — full drug profile →

Conditions studied

Gonococcal (GC) Infection — all drugs for Gonococcal (GC) Infection →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, any sex, with Gonococcal (GC) Infection. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Description of the safety profile in terms of adverse events; blood pressure, heart rate and body temperature; electrocardiograms; telemetry; clinical chemistry ; haematology and physical examination
Time frame: From admission on day -1 until follow up. ( Max 16 days)
Applies to Part A and B

Sponsor's own description

The purpose of this study is to assess the safety and tolerability of orally administered AZD0914 in healthy adult subjects.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Preparing for an era of untreatable gonorrhea.
Barbee LA. · · 2014 · cited 38× · PMID 24685549 · DOI 10.1097/qco.0000000000000058
Single-Dose Pharmacokinetics, Excretion, and Metabolism of Zoliflodacin, a Novel Spiropyrimidinetrione Antibiotic, in Healthy Volunteers.
O'Donnell J, Lawrence K, Vishwanathan K, Hosagrahara V, et al · · 2019 · cited 18× · PMID 30373802 · DOI 10.1128/aac.01808-18
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.
Cristillo AD, Bristow CC, Torrone E, Dillon JA, et al · · 2019 · cited 15× · PMID 30363025 · DOI 10.1097/olq.0000000000000929
Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.
Newman LM, Kankam M, Nakamura A, Conrad T, et al · · 2021 · cited 7× · PMID 34606332 · DOI 10.1128/aac.01292-21

Verify or expand the search:

Other trials of Part A

Trials testing the same drug.

NCT05082051 — Oral CDX-7108 in Healthy Adults and EPI Subjects · Phase 1 · completed
NCT04510649 — Surufatinib DDI With a PPI and a CYP3A Inducer · Phase 1 · completed
NCT03474640 — Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies · Phase 1 · completed

Other recruiting trials for Gonococcal (GC) Infection

Currently open trials in the same condition.

NCT06897943 — Epidemiology of Gonococcal Arthritis (EpGAr) · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01929629 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 14 April 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01929629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing